The performance of companies tied to the drug's past presents a challenging investment landscape. While the initial boom generated substantial gains, generic copies have significantly diminished sales . Investing in connected pharmaceutical firms now requires a careful assessment of proprietary protection , evolving medical trends , and the potenti